Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoki Terada

Showing results (171-180 of 185) with videos related to

Pageof 19
Sort By:
International Journal of Urology : Official Journal of the Japanese Urological Association|December 26, 2023
GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401Akira Yokomizo, Masaki Shiota, Futoshi Morokuma, et al.
European Urology Oncology|June 16, 2019
Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate CancerShusuke Akamatsu, Masashi Kubota, Ryuji Uozumi, et al.
Scientific Reports|July 3, 2024
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancerShinichi Sakamoto, Kodai Sato, Takahiro Kimura, et al.
BMC Cancer|March 12, 2021
Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative studyMakito Miyake, Kota Iida, Nobutaka Nishimura, et al.
Hinyokika Kiyo. Acta Urologica Japonica|January 7, 2020
[The Safety of Laparoscopic Radical Cystectomy during Initial Phases in a Japanese Multicenter Cohort]Toru Kanno, Takahiro Inoue, Katsuhiro Ito, et al.
JNCI Cancer Spectrum|February 4, 2022
Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate BiopsyShusuke Akamatsu, Naoki Terada, Ryo Takata, et al.
BMC Cancer|February 17, 2019
The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patientsNaoki Terada, Toshiyuki Kamoto, Hiromasa Tsukino, et al.
BJUI Compass|April 27, 2022
Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancerNaoki Terada, Takashi Mizowaki, Toshihiro Saito, et al.
International Journal of Clinical Oncology|December 17, 2024
Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancerTokiyoshi Tanegashima, Masaki Shiota, Naoki Terada, et al.
Annals of Surgical Oncology|February 14, 2024
Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical ProstatectomyMasaki Shiota, Dai Takamatsu, Yoshiyuki Matsui, et al.
Pageof 19

Showing results (171-180 of 185) with videos related to

Sort By:
Pageof 19
International Journal of Urology : Official Journal of the Japanese Urological Association|December 26, 2023
GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401Akira Yokomizo, Masaki Shiota, Futoshi Morokuma, et al.
European Urology Oncology|June 16, 2019
Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate CancerShusuke Akamatsu, Masashi Kubota, Ryuji Uozumi, et al.
Scientific Reports|July 3, 2024
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancerShinichi Sakamoto, Kodai Sato, Takahiro Kimura, et al.
BMC Cancer|March 12, 2021
Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative studyMakito Miyake, Kota Iida, Nobutaka Nishimura, et al.
Hinyokika Kiyo. Acta Urologica Japonica|January 7, 2020
[The Safety of Laparoscopic Radical Cystectomy during Initial Phases in a Japanese Multicenter Cohort]Toru Kanno, Takahiro Inoue, Katsuhiro Ito, et al.
JNCI Cancer Spectrum|February 4, 2022
Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate BiopsyShusuke Akamatsu, Naoki Terada, Ryo Takata, et al.
BMC Cancer|February 17, 2019
The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patientsNaoki Terada, Toshiyuki Kamoto, Hiromasa Tsukino, et al.
BJUI Compass|April 27, 2022
Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancerNaoki Terada, Takashi Mizowaki, Toshihiro Saito, et al.
International Journal of Clinical Oncology|December 17, 2024
Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancerTokiyoshi Tanegashima, Masaki Shiota, Naoki Terada, et al.
Annals of Surgical Oncology|February 14, 2024
Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical ProstatectomyMasaki Shiota, Dai Takamatsu, Yoshiyuki Matsui, et al.
Pageof 19